Cytokinetics, Bayer in Japan Licensing Pact for Aficamten

Dow Jones11-19

By Colin Kellaher

Cytokinetics has struck a deal potentially worth hundreds of millions of dollars to license its promising heart drug aficamten to Bayer in Japan.

Cytokinetics on Tuesday said it will receive an upfront payment of 50 million euros ($52.8 million) and will be eligible to receive up to an additional EUR90 million upon the achievement of milestones through commercial launch.

The South San Francisco, Calif., biopharmaceutical company said it is also eligible to receive up to EUR490 million in commercial milestone payments, along with royalties on sales of the drug in Japan.

German drugs-to-crops giant Bayer will have an exclusive license to develop and commercialize aficamten in Japan.

Cytokinetics has filed for U.S. Food & Drug Administration approval of aficamten in hypertrophic cardiomyopathy, the most common genetic heart disease, and has said it expects to file for European approval by the end of the year.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 19, 2024 06:38 ET (11:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484917306?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484917306","market":"hk","top_or_hot":-1,"title":"Cytokinetics, Bayer in Japan Licensing Pact for Aficamten","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> has struck a deal potentially worth hundreds of millions of dollars to license its promising heart drug aficamten to Bayer in Japan. \n</p>\n<p>\n  Cytokinetics on Tuesday said it will receive an upfront payment of 50 million euros ($52.8 million) and will be eligible to receive up to an additional EUR90 million upon the achievement of milestones through commercial launch. \n</p>\n<p>\n  The South San Francisco, Calif., biopharmaceutical company said it is also eligible to receive up to EUR490 million in commercial milestone payments, along with royalties on sales of the drug in Japan. \n</p>\n<p>\n  German drugs-to-crops giant Bayer will have an exclusive license to develop and commercialize aficamten in Japan. \n</p>\n<p>\n  Cytokinetics has filed for U.S. Food &amp; Drug Administration approval of aficamten in hypertrophic cardiomyopathy, the most common genetic heart disease, and has said it expects to file for European approval by the end of the year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 19, 2024 06:38 ET (11:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics, Bayer in Japan Licensing Pact for Aficamten</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics, Bayer in Japan Licensing Pact for Aficamten\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\nCytokinetics has struck a deal potentially worth hundreds of millions of dollars to license its promising heart drug aficamten to Bayer in Japan. \n\n\n  Cytokinetics on Tuesday ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484917306","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484917306","pubTimestamp":1732016280,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cytokinetics has struck a deal potentially worth hundreds of millions of dollars to license its promising heart drug aficamten to Bayer in Japan.Cytokinetics on Tuesday said it will receive an upfront payment of 50 million euros  and will be eligible to receive up to an additional EUR90 million upon the achievement of milestones through commercial launch.The South San Francisco, Calif., biopharmaceutical company said it is also eligible to receive up to EUR490 million in commercial milestone payments, along with royalties on sales of the drug in Japan.German drugs-to-crops giant Bayer will have an exclusive license to develop and commercialize aficamten in Japan.Cytokinetics has filed for U.S. Food & Drug Administration approval of aficamten in hypertrophic cardiomyopathy, the most common genetic heart disease, and has said it expects to file for European approval by the end of the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CYTK":"Cytokinetics","BK4585":"ETF&股票定投概念","BAYRY":"Bayer A.G.","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"Cytokinetics与拜耳在日本签署Aficamten许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1,"BAYRY":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\nCytokinetics has struck a deal potentially worth hundreds of millions of dollars to license its promising heart drug aficamten to Bayer in Japan. \n\n\n  Cytokinetics on Tuesday said it will receive an upfront payment of 50 million euros ($52.8 million) and will be eligible to receive up to an additional EUR90 million upon the achievement of milestones through commercial launch. \n\n\n  The South San Francisco, Calif., biopharmaceutical company said it is also eligible to receive up to EUR490 million in commercial milestone payments, along with royalties on sales of the drug in Japan. \n\n\n  German drugs-to-crops giant Bayer will have an exclusive license to develop and commercialize aficamten in Japan. \n\n\n  Cytokinetics has filed for U.S. Food & Drug Administration approval of aficamten in hypertrophic cardiomyopathy, the most common genetic heart disease, and has said it expects to file for European approval by the end of the year. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2024 06:38 ET (11:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484917306"}